Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer

Simple Summary The prognostic impact of the different tumor-infiltrating lymphocyte (TIL) subpopulations remains debated in solid cancers. We investigated the clinicopathological correlates and prognostic impact of TILs, particularly of γδ T cells, in 162 triple-negative breast cancer (TNBC) patients. A high γδ T cell density was significantly associated with younger age, higher tumor histological grade, adjuvant chemotherapy, BRCA1 promoter methylation, TIL density, and PD-L1 and PD-1 expression. In multivariate analyses, γδ T cell infiltration was an independent prognostic factor. However, this prognostic impact varied according to the tumor PIK3CA mutational status. High γδ T cell infiltration was associated with better survival in patients with PIK3CA wild-type tumors, without significant difference in the PIK3CA-mutated tumor subgroup. Altogether, these data suggest that high γδ T cell infiltrate is correlated with immune infiltration and might represent a prognostic tool in TNBC patients. Abstract The prognostic impact of the different tumor-infiltrating lymphocyte (TIL) subpopulations in solid cancers is still debated. Here, we investigated the clinicopathological correlates and prognostic impact of TILs, particularly of γδ T cells, in 162 patients with triple-negative breast cancer (TNBC). A high γδ T cell density (>6.625 γδ T cells/mm2) was associated with younger age (p = 0.008), higher tumor histological grade (p = 0.002), adjuvant chemotherapy (p = 0.010), BRCA1 promoter methylation (p = 0.010), TIL density (p < 0.001), and PD-L1 (p < 0.001) and PD-1 expression (p = 0.040). In multivariate analyses, γδ T cell infiltration (cutoff = 6.625 γδ T cells/mm2) was an independent prognostic factor (5-year relapse-free survival: 63.3% vs. 89.8%, p = 0.027; 5-year overall survival: 73.8% vs. 89.9%, p = 0.031, for low vs. high infiltration). This prognostic impact varied according to the tumor PIK3CA mutational status. High γδ T cell infiltration was associated with better survival in patients with PIK3CA wild-type tumors, but the difference was not significant in the subgroup with PIK3CA-mutated tumors. Altogether, these data suggest that high γδ T cell infiltrate is correlated with immune infiltration and might represent a candidate prognostic tool in patients with TNBC.

[1]  W. Jacot,et al.  Prognostic Value of CXCR2 in Breast Cancer , 2020, Cancers.

[2]  M. Dieci,et al.  Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. , 2020, European journal of cancer.

[3]  L. Bao,et al.  High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization , 2020, Frontiers in Pharmacology.

[4]  P. Lamy,et al.  BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer , 2020, Cancers.

[5]  J. Bolen,et al.  Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies , 2020, Frontiers in Cell and Developmental Biology.

[6]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[7]  K. Heise,et al.  γδ T-cell Receptors Derived from Breast Cancer–Infiltrating T Lymphocytes Mediate Antitumor Reactivity , 2020, Cancer Immunology Research.

[8]  Seung-Oe Lim,et al.  Oncogenic signaling pathways associated with immune evasion and the resistance to immune checkpoint inhibitors in cancer. , 2019, Seminars in cancer biology.

[9]  Zhongtao Zhang,et al.  Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis , 2019, BMC Cancer.

[10]  H. Ellis,et al.  PI3K Inhibitors in Breast Cancer Therapy , 2019, Current Oncology Reports.

[11]  E. Winer,et al.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[12]  H. Horlings,et al.  Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes , 2019, Breast Cancer Research.

[13]  Y. Allory,et al.  Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer , 2019, Oncoimmunology.

[14]  S. O'Reilly,et al.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[15]  Melissa A. Wilson,et al.  The neoepitope landscape of breast cancer: implications for immunotherapy , 2019, BMC Cancer.

[16]  F. Bertucci,et al.  Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype , 2018, PloS one.

[17]  C. Fan,et al.  Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast , 2018, Cell reports.

[18]  G. Romieu,et al.  Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers , 2018, British Journal of Cancer.

[19]  Dorte Nielsen,et al.  Triple negative breast cancer – prognostic role of immune-related factors: a systematic review , 2018, Acta oncologica.

[20]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[21]  C. Sotiriou,et al.  An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers , 2016, Breast Cancer Research.

[22]  Harold L. Moses,et al.  Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection , 2016, PloS one.

[23]  G Pruneri,et al.  Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Michael F. Berger,et al.  Genetic Alterations of Triple Negative Breast Cancer By Targeted Next Generation Sequencing And Correlation With Tumor Morphology , 2016, Modern Pathology.

[25]  P. Colombo,et al.  High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers , 2015, BMC Cancer.

[26]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[27]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  E. Ibrahim,et al.  The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis , 2014, Breast Cancer Research and Treatment.

[29]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Romieu,et al.  BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer , 2013, BMC Cancer.

[31]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[32]  Raphaël Porcher,et al.  Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 , 2013, Breast Cancer Research.

[33]  C. Perou,et al.  Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. , 2013, The oncologist.

[34]  G. Romieu,et al.  Adjuvant early breast cancer systemic therapies according to daily used technologies. , 2012, Critical reviews in oncology/hematology.

[35]  G. Romieu,et al.  Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles , 2011, Breast Cancer Research.

[36]  J. Lee,et al.  Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC) , 2011, Cancer Chemotherapy and Pharmacology.

[37]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[38]  Pierre-Marie Martin,et al.  Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers , 2011, Breast Cancer Research.

[39]  M. Bonneville,et al.  γδ T cell effector functions: a blend of innate programming and acquired plasticity , 2010, Nature Reviews Immunology.

[40]  S. Narod,et al.  Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[41]  W. Born,et al.  IL‐17‐producing γδ T cells , 2009, European Journal of Immunology.

[42]  F. Waldman,et al.  PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer , 2009, Oncogene.

[43]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[44]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[45]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[46]  M. Raspollini,et al.  Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[49]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[50]  C. Sotiriou,et al.  Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer , 2017, Journal of the National Cancer Institute.

[51]  M. Quinn,et al.  Low dose cyclophosphamide: Mechanisms of T cell modulation. , 2016, Cancer treatment reviews.

[52]  K. Boudjema,et al.  Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. , 2008, Cancer immunology, immunotherapy : CII.

[53]  Helen Y Wang,et al.  Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. , 2007, Immunity.

[54]  M. Bonneville,et al.  V gamma 9V delta 2 T cell response to colon carcinoma cells. , 2005, Journal of immunology.